MedTrace Logo

A Study in Patients With Advanced Cancers

NCT05320588 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2022-07-19

No results posted yet for this study

Summary

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

Conditions

Interventions

DRUG

BIO-106

BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)

DRUG

Pembrolizumab

Programmed death receptor-1 (PD 1)-blocking antibody

Sponsors & Collaborators

  • BiOneCure Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • BiOneCure Clinical Development · BiOneCure Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2024-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05320588 on ClinicalTrials.gov